Drug Search Results
More Filters [+]

Talnetant

Alternative Names: talnetant
Latest Update: 2017-08-16
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: NK3 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Talnetant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Schizophrenia|Irritable Bowel Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT00300963

P2

Completed

Schizophrenia

2005-10-01

SB-223412/093

P2

Completed

Schizophrenia

2005-10-01

2004-000848-24

P2

Completed

Irritable Bowel Syndrome

2005-07-26

NCT00101985

P2

Completed

Irritable Bowel Syndrome

2005-07-01

Recent News Events

Date

Type

Title